You are here
MOLECULES FOR HEALTH, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Ribonucleotide Reductase Inhibitors for Restenosis
Amount: $225,698.00DESCRIPTION (provided by applicant): Coronary artery disease is a major health problem and the leading cause of premature death in the US. Percutaneous coronary intervention with stenting is the prima ...
SBIRPhase I2008Department of Health and Human Services National Institutes of Health -
Radical Scavengers for Brain Ischemia Reperfusion injury
Amount: $100,000.00DESCRIPTION (provided by applicant): The goal of this proposal is to determine the potential of two MFH free radical scavenging compounds, Didox and Imidate, to protect brain tissue from stroke inj ...
SBIRPhase I2003Department of Health and Human Services National Institutes of Health -
Novel Cancer Drugs to Prevent Doxorubicin Toxicity
Amount: $107,767.00DESCRIPTION (provided by applicant): Doxorubicin, an anthracycline drug, is effective against numerous solid and hematological cancers, but cardiotoxicity limits its usefulness. The spe ...
SBIRPhase I2001Department of Health and Human Services National Institutes of Health -
Ribonucleotide Reductase Inhibitors for AIDS Therapy
Amount: $749,713.00We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotida ...
SBIRPhase II1998Department of Health and Human Services -
Ribonucleotide Reductase Inhibitors for AIDS Therapy
Amount: $99,794.00We will develop a series of Ribonucleotide reductase inhibitors for the treatment of retrovirus (AIRibonucleotide reductase catalyzes the reductive conversion of ribonucleotides to deoxyribonucleotida ...
SBIRPhase I1995Department of Health and Human Services -
NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY
Amount: $499,963.00THIS RESEARCH IS BASED ON THE THESIS THAT OXYGEN-FREE RADICALS CONTRIBUTE IN A SIGNIFICANT WAY TO THE DELETERIOUS ASPECT OF REPERFUSION AFTER A TISSUE OR ORGAN IS DEPRIVED OFOXYGEN AND FLOW IS RE-INIT ...
SBIRPhase II1993Department of Health and Human Services -
POTENTIAL NEW TOPICAL ANTI-PSORIASIS AGENTS
Amount: $49,998.00PSORIASIS AFFECTS APPROXIMATELY 2 PERCENT OF THE U. S. POPULATION AND MOST PRESENT TREATMENTS ARE EITHER POTENTIALLY HARMFUL OR ENTAIL DIFFICULT AND/OR UNPLEASANT PROCEDURES. THEREFORE NEW AGENTS ARE ...
SBIRPhase I1991Department of Health and Human Services -
NEW DRUGS TO PREVENT REPERFUSION ISCHEMIA INJURY
Amount: $49,000.00N/A
SBIRPhase I1990Department of Health and Human Services -
POLYHYDROXYPHENYL-CONJUGATES FOR ANTITUMOR ACTIVITY
Amount: $49,962.00THE REDUCTIVE CONVERSION OF RIBONUCLEOTIDES TO DEOXYRIBONUCLEOTIDES, CATALYZED BY RIBONUCLEOTIDE REDUCTASE,IS A CRUCIAL AND RATE-LIMITING REACTION IN THE DNA BIOSYNTHETIC PATHWAY, AND REPRESENTS A LOG ...
SBIRPhase I1989Department of Health and Human Services -
POLYHYDROXYPHENYL DERIVATIVES DESIGNED FOR ANTITUMOR ACTIVITY
Amount: $50,000.00THE REDUCTIVE CONVERSION OF RIBONUCLEOTIDES TO DEOXYRIBONUCLEOTIDES, CATALYZED BY RIBONUCLEOTIDE REDUCTASE,IS A CRUCIAL AND RATE-LIMITING REACTION IN THE DNA BIOSYNTHETIC PATHWAY. THIS REACTION, THERE ...
SBIRPhase I1987Department of Health and Human Services